Cancers with low levels of CD8+ T-cell infiltration, indicating a lack of immune access to a tumor, or high PD-L1 expression, signaling a blunting of the host immune response, are less likely to respond to immune mobilization via immunotherapy. This evidence concerns the gene CD274 and cancer.